April 8, 2019
The AAAAI was joined by the Allergy and Asthma Foundation of America, the American Partnership for Eosinophilic Disorders,
and The Mastocytosis Society in a letter expressing concern for both patient access and economic implications of a proposed rule,
Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for
Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.
Read the letter here.